| Dr John P Tortu, | |
|
4221 W Lincoln Hwy, Parkesburg, PA 19365 | |
| (484) 401-1405 | |
| Not Available |
| Full Name | Dr John P Tortu |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 4221 W Lincoln Hwy, Parkesburg, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053521526 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 25MB07319900 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr John P Tortu, 407 Continental Ave, Coatesville, PA 19320-1604 Ph: (484) 401-1405 | Dr John P Tortu, 4221 W Lincoln Hwy, Parkesburg, PA 19365 Ph: (484) 401-1405 |
News Archive
A new research study has revealed an important relationship between proteins secreted by the heart and obesity, glucose intolerance, and insulin resistance. The findings, published today in Obesity, offer a new approach to treating metabolic disorders, including type 2 diabetes, by targeting the pathway that controls the proteins' concentration in the blood.
Adolescents and young adults are most likely to abuse prescription medications. Yet prescription rates for controlled medications, or drugs the Drug Enforcement Administration deems as having the potential for abuse, have nearly doubled for those age groups in the past 14 years, according to a recent study published in Pediatrics. Overall, a controlled medication was prescribed for young adults at approximately one out of every six visits and for young adult by adolescents one out of every nine encounters.
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
The course of bipolar II disorder can follow several distinct trajectories, with a major depressive episode being the most common presenting feature, a study of Japanese patients suggests.
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the first patient has initiated treatment in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Initial top-line results are expected in mid-2010.
› Verified 8 days ago
Dr. Emilia Anntionette Cuneo, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 950 S Octorara Trl, Parkesburg, PA 19365 Phone: 610-857-6648 Fax: 610-857-6638 | |
Dr. Glenn Ortley, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 950 S Octorara Trl, Parkesburg, PA 19365 Phone: 610-857-6639 Fax: 610-857-6649 | |
Lizette Perez Nolt, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 950 S Octorara Trl, Parkesburg, PA 19365 Phone: 610-857-6648 Fax: 610-857-6638 |